Tweets
It is NO LONGER a ACCEPTABLE
To NOT consider
#MMF or #Cyclo + another proven #Rx
Added to
#HCQ and #tapering /limiting #glucocorticoids
RCTs in #lupus #nephritis support this
? Is which to add
#belimumab
#CNI #volclosporin
#obinutuzimab
#ACR #ACRbest @RheumNow @ACRheum https://t.co/a7WMFfCyXl
Janet Pope @Janetbirdope ( View Tweet )
1 year 5 months ago
RheumNow’s expanded coverage of #ACR24 is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its faculty
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
Paraoxonase-1: Possible Biomarker for Progression to RA
Dr. Jonathan Kay discusses abstract 0464, Increases in Paraoxonase-1 Activity over Time Associates with Reduced Risk of Incident Inflammatory Arthritis in an Anti-Citrullinated Protein Antibody-Positive Population,… https://t.co/yhcCrrvjxH https://t.co/caf5dUvrOQ
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
JAK-pot! How fast do DMARDs work?
Dr. Mike Putman interviews Dr. Kim Lauper about abstract 0501, How Fast Do JAK-inhibitors, TNF-inhibitors, Abatacept and IL-6 Inhibitors Act in Rheumatoid Arthritis? An International Collaboration of Registers of Rheumatoid Arthritis Patients… https://t.co/GO9EwyrVpV https://t.co/lELE5SJW5i
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
PREDICT-SpA: Evaluating the influence of gender on disease assessment tools
Dr. Sheila Reyes reports on abstract 0571, Gender-specific Performance of Disease Activity Assessment Tools in Axial Spondyloarthritis: Ancillary Analysis of the PREDICT-SpA Study, presented at #ACR24.… https://t.co/EGlCap6pEw
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
@DrLisaCS distills the challenges of MCTD 👇
🔵Clinical phenotyping key to improve patient outcomes
@jhrheumatology @RheumNow #acr24
https://t.co/APfXPwxvfE
Caoilfhionn Connolly @CaoilfhionnMD ( View Tweet )
1 year 5 months ago
Continuing or Stopping Low Dose Glucocorticoids in GPA
Dr. Mike Putman reports about plenary session abstract 0774 (the TAPIR study) about how and when patients can stop steroids in GPA. #ACR24
https://t.co/OWqN0jmkc1 https://t.co/foOaVRtGiV
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
RheumNow’s expanded coverage of the #ACR24 meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its Faculty.
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
RheumNow Day 3 Recap: ACR Convergence 2024 Highlights https://t.co/jFIATPKlp7
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
I've shared some thoughts on @RheumNow on methotrexate, tocilizumab, and baricitinib in PMR based on #ACR24 https://t.co/WXiW1nLN4k
Richard Conway @RichardPAConway ( View Tweet )
1 year 5 months ago
TNFis preventing cancer compared to placebo, and JAKi being neutral to placebo and maybe preventing haem cancers also. #ACR24 abstract 0989 was certainly provocative. I've shared my thoughts on @RheumNow https://t.co/yQFoUGifEN
Richard Conway @RichardPAConway ( View Tweet )
1 year 5 months ago
Pathophysiological pathways in neuropsychiatric SLE. 2 components:
-Ischaemic
-Inflammatory
Zahi Touma @RheumNow #ACR24 https://t.co/wwlSSSpOIU
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
1 year 5 months ago
